Delving into the Latest Updates on Dexamethasone Acetate with Synapse

主要目的：评价浙江仙琚制药股份有限公司研发的醋酸地塞米松片（规格：0.75mg）在中国健康受试者中单次空腹/餐后口服后的体内药物代谢动力学过程，估算相应的药代动力学参数，并以Sanofi Aventis France公司为持证商的原研药物醋酸地塞米松片（规格：0.5mg，商品名：Dectancyl®）为参比制剂，对两种制剂进行生物等效性评价。次要目的：评价空腹和餐后给药条件下，中国健康受试者单次口服醋酸地塞米松片受试制剂和参比制剂后的安全性。

[Translation]

Main purpose: To evaluate the in vivo pharmacokinetic process of dexamethasone acetate tablets (specification: 0.75 mg) developed by Zhejiang Xianju Pharmaceutical Co., Ltd. after a single fasting/postprandial oral administration in Chinese healthy subjects, and estimate the corresponding Pharmacokinetic parameters, and using the original drug dexamethasone acetate tablets (specification: 0.5 mg, trade name: Dectancyl®) of Sanofi Aventis France as the license holder as the reference preparation, the bioequivalence of the two preparations was conducted evaluate. Secondary purpose: To evaluate the safety of the test and reference preparations of dexamethasone acetate tablets administered to Chinese healthy subjects after a single oral administration under fasting and postprandial administration conditions.

Start Date28 Dec 2023

Sponsor / Collaborator

Zhejiang Xianju Pharmaceutical Co., Ltd.

NCT05231629 / RecruitingPhase 2IIT

MRD-Guided Sequential Therapy For Deep Response in Newly Diagnosed Multiple Myeloma - MASTER-2 Trial

This research study will determine the proportion of patients with lowest minimal residual disease (MRD) response obtainable after receiving 6 cycles of study treatment. Minimal residual disease is multiple myeloma cells below the level of 1 cancer cell out of 100,000 in the bone marrow.
For patients who become MRD "negative" (i.e. less than 1 cancer cell out of 100,000) at the end of 6 cycles of therapy, this study will study if that good response can be maintained with 3 additional cycles of treatment instead of use of autologous hematopoietic cell transplantation (AHCT).
For patients who are MRD "positive" at the end of 6 cycles of therapy, this study will answer whether more patients can become and remain MRD "negative" with AHCT plus teclistamab in combination with daratumumab when compared with patients who undergo AHCT followed by lenalidomide (an established anti-myeloma drug) plus daratumumab.

Start Date13 Dec 2023

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

CTR20232986 / CompletedNot Applicable

醋酸地塞米松片在健康受试者中单中心、随机、开放、两制剂、单次给药、两周期、双交叉空腹/餐后生物等效性试验

[Translation] Single-center, randomized, open-label, two-preparation, single-dose, two-cycle, double-crossover fasting/postprandial bioequivalence trial of dexamethasone acetate tablets in healthy subjects

主要目的：以药代动力学参数作为主要终点评价指标，分别比较在空腹/餐后状态下口服受试制剂醋酸地塞米松片（生产厂家：新乡市常乐制药有限责任公司）与参比制剂醋酸地塞米松片（持证商：SANOFI AVENTIS FRANCE，商品名：Dectancyl®）后在健康受试者体内的药代动力学行为，评价两种制剂的生物等效性。次要目的：观察受试制剂醋酸地塞米松片和参比制剂醋酸地塞米松片在健康受试者中的安全性。

[Translation]

Main purpose: Using pharmacokinetic parameters as the primary endpoint evaluation index, compare the oral administration of the test preparation dexamethasone acetate tablets (manufacturer: Xinxiang Changle Pharmaceutical Co., Ltd.) and the reference preparation in the fasting/postprandial state. The pharmacokinetic behavior of dexamethasone acetate tablets (licensee: SANOFI AVENTIS FRANCE, trade name: Dectancyl®) in healthy subjects was evaluated to evaluate the bioequivalence of the two preparations. Secondary purpose: To observe the safety of the test preparation dexamethasone acetate tablets and the reference preparation dexamethasone acetate tablets in healthy subjects.

Start Date29 Oct 2023

Sponsor / Collaborator

Xinxiang Changle Pharmaceutical Co. Ltd.

100 Clinical Results associated with Dexamethasone Acetate

Login to view more data

100 Translational Medicine associated with Dexamethasone Acetate

Login to view more data

100 Patents (Medical) associated with Dexamethasone Acetate

Login to view more data

275

Literatures (Medical) associated with Dexamethasone Acetate

01 Apr 2024·Macromolecular Bioscience

Colon‐Targeted Oral Delivery of Hydroxyethyl Starch–Curcumin Microcapsules Loaded with Multiple Drugs Alleviates DSS‐Induced Ulcerative Colitis in Mice

Article

Author: Xu, Chenlan ; Xu, Zhenjin ; Zhang, Wancong ; Zou, Minglang ; Wang, Yongming ; Weng, Zuquan ; Tang, Shijie ; Huang, Da

AbstractCombination therapy through colon‐targeted oral delivery of multiple drugs presents a promising approach for effectively treating ulcerative colitis (UC). However, the codelivery of drugs with diverse physicochemical properties in a single formulation remains a formidable challenge. Here, microcapsules are designed based on hydroxyethyl starch–curcumin (HES─CUR) conjugates to enable the simultaneous delivery of hydrophobic dexamethasone acetate (DA) and hydrophilic cefazolin sodium (CS), yielding multiple drug‐loaded microcapsules (CS/DA‐loaded HES─CUR microcapsules, CDHC‐MCs) tailored for colon‐targeted therapy of UC. Thorough characterization confirms the successful synthesis and exceptional biocompatibility of CDHC‐MCs. Biodistribution studies demonstrate that the microcapsules exhibit an impressive inflammatory targeting effect, accumulating preferentially in inflamed colons. In vivo experiments employing a dextran‐sulfate‐sodium‐induced UC mouse model reveal that CDHC‐MCs not only arrest UC progression but also facilitate the restoration of colon length and alleviate inflammation‐related splenomegaly. These findings highlight the potential of colon‐targeted delivery of multiple drugs within a single formulation as a promising strategy to enhance UC treatment, and the CDHC‐MCs developed in this study hold great potential in developing novel oral formulations for advanced UC therapy.

01 Dec 2023·Chinese Journal of Chromatography

Simultaneous determination of 83 glucocorticoids in cosmetics by ultra performance liquid chromatography-tandem mass spectrometry

Article

Author: Meng, Yaping ; Li, Xiangsheng ; Liu, Hua ; Li, Xiang ; Zhao, Qianru ; Gao, Ruifang

Glucocorticoids, which are a class of steroidal hormones secreted by the adrenal cortex, have significant anti-inflammatory, immunosuppressive, and anti-allergic effects. Thus, these compounds are widely used in clinical practice. However, the long-term use of cosmetics containing glucocorticoids can lead to serious consequences, such as hormone-dependent dermatitis, hypertension, and other serious injuries. The Safety and Technical Specification for Cosmetics (2015 edition) and Regulation (EC) No. 1223/2009 of the European Parliament and Council on cosmetic products list glucocorticoids as prohibited raw materials. According to the National Medical Products Administration, reports on the illegal addition of glucocorticoids to cosmetics by manufacturers have increased in recent years. Therefore, establishing high-throughput screening methods to ensure the quality and safety of cosmetics is imperative. In this study, a comprehensive analytical method based on ultra performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS) was developed for the rapid screening of 83 glucocorticoids in cosmetics. A series of conditions were optimized using three matrices that are commonly used in cosmetics: water, lotion, and cream (o/w-type). Four mobile-phase systems and three chromatographic columns were then optimized to achieve the best separation effects. Various MS parameters, such as the capillary voltages, cone voltages, desolvation gas flow rates, and collision energies of the ion pairs of the target compounds, were also optimized. Furthermore, pretreatment was essential for glucocorticoid determination owing to the complex matrix effects of cosmetics. The analytes were divided into two groups, with lg K_ow=4 as the limit, to compare the effects of the extraction solvent on recoveries. The extraction recoveries of target analytes with six extraction methods, namely, extraction with acetonitrile, extraction with acetone, extraction with ethyl acetate, dispersion in saturated sodium chloride solution followed by extraction with acetonitrile, dispersion in saturated sodium chloride solution followed by extraction with acetone, and dispersion in saturated sodium chloride solution followed by extraction with ethyl acetate, were compared. The recoveries from QuEChERS and solid-phase extraction (SPE) purification were also compared. Based on the experimental results, the final sample pretreatment method included acetonitrile vortex dispersion, ultrasonic extraction, and sample loading after filtration. The 83 target compounds were separated on a Thermo Accucore PFP column (100 mm×2.1 mm, 2.6 μm) with 0.1% (v/v) acetic acid in acetonitrile and 0.1% (v/v) acetic acid in water as the mobile phases. The analytes were determined by dynamic multiple-reaction monitoring (MRM) in electrospray positive ionization mode (ESI⁺) and quantified using the external standard method. Matrix standard curves were used to reduce matrix effects. The calibration curves of the 83 target compounds were linear in the mass concentration range of 2-200 μg/L (r>0.995). At three levels of addition, the recoveries were 74.5%-112.4%, and the relative standard deviations (RSDs, n=6) were 0.8%-9.9%. The limits of detection (LODs, S/N≥3) were 0.001-0.023 μg/g, and the limits of quantification (LOQs, S/N≥10) were 0.002-0.076 μg/g. The developed method was used to detect glucocorticoids in 41 cosmetic samples. Fluocinolone acetonide, beclomethasone dipropionate, desonide 21-acetate, and desonide were detected in four samples. The content range of glucocorticoids in the positive samples was 0.53-634.27 μg/g. Notably, desonide 21-acetate, which is not included in the scope of the statutory detection method, was detected in two batches of samples. In conclusion, the proposed method is simple, sensitive, reliable, and suitable for the high-throughput analysis of the 83 glucocorticoids in cosmetics with different matrices. This method could provide reliable technical support for the daily supervision of cosmetics and serve as a supplement to current glucocorticoid standards.

01 Oct 2023·International Journal of Pharmaceutics

Unidirectional drug release from 3D printed personalized buccal patches using FDM technology

Article

Author: Wang, Xiangyu ; Pan, Hao ; Li, Xin ; Gong, Ye ; Chen, Hao ; Bu, Tianshi

Oromucosal delivery of active ingredients of drugs provides a superior administration route for the treatment of oral diseases, due to avoidance of the first pass effect. In the present work, in view of the characteristics of large differences between oral ulcer symptoms and different lesion sizes, dexamethasone acetate unidirectional drug release buccal patches has been prepared based on Fused Deposition Modelling (FDM). Unidirectional drug release was achieved by covering the top and side with ethyl cellulose. Polyvinyl alcohol as a drug carrier, xylitol as a plasticizer. First, the protection effect of different thicknesses of the protective layer is investigated to determine the thickness of the protective layer. Co-extrusion printing method was adapted, utilizing blank filament to regulate preparations with different areas' drug loading. The results show that co-extrusion had no significant impact on the overall patches' drug release and adhesion properties. The physicochemical properties of the patches were also characterized. Evaluation of irritation is showed that these patches do not cause irritation to the oral mucosa of rats. Pharmacodynamic evaluation results showed that the preparation could promote the reduction of ulcer area. The results showed that FDM printing is a convenient and practical approach in manufacturing buccal patches.

8

News (Medical) associated with Dexamethasone Acetate

03 Apr 2024

·www.biospace.com

ProMed Pharma Acquires SpineThera Manufacturing Capabilities and an Option to License Intellectual Property

PLYMOUTH, Minn.--(BUSINESS WIRE)-- SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for epidural injection for the management of lumbar radicular pain) and ProMed Pharma LLC, a leading contract manufacturer of polymer-based drug releasing dosage forms and combination device components, announced today that ProMed Pharma has acquired SpineThera’s cGMP manufacturing operational assets. ProMed Pharma also obtained an option to license SpineThera’s microsphere intellectual property with the potential to sub-license to ProMed Pharma’s customers. With this acquisition, ProMed Pharma adds biodegradable microparticle development and manufacturing services to its existing portfolio of polymer-based drug releasing dosage forms by purchasing SpineThera’s controlled environment manufacturing suite and process equipment that provide a robust manufacturing process supported by a cGMP quality management system and a highly experienced CMC team. SpineThera has been developing and manufacturing biodegradable microspheres for 10 years. The sale of its manufacturing operation is consistent with SpineThera’s drug-product asset-development focus. SpineThera’s Chief Executive Officer, Jeff Missling, remarked, “We are focused on improving patients lives by developing innovative injectable drugs based on our proprietary micro-suspension platform technology. Our lead asset, SX600, has shown best-in-class potential for the treatment of lumbar radicular pain. Importantly, SpineThera is maintaining exclusive ownership of intellectual property that enables SX600. With this transaction, our manufacturing team joins a highly capable CDMO, ProMed Pharma, a company we have worked with closely for many years. SpineThera becomes a customer of ProMed, who will manufacture SX600 in the same cleanroom in which we previously developed the technology and manufactured clinical batches. This transaction provides an infusion of working capital and reduces our fixed and recurring expenses.” Missling added, “I thank our employees who have made the transition to ProMed for their years of dedicated service at SpineThera. We look forward to continuing to partner to advance the development of SX600 so that patients suffering from severe lumbar radicular pain may have greatly improved pain management.” “Microparticle formulation capabilities will significantly expand the sustained-release options we can offer our partners,” commented Jim Arps, Director of Business Development at ProMed Pharma. “I’m particularly excited about opportunities to expand our collaborations in Women’s Health, Ophthalmology, and Complex Generics and engage new partners in therapeutic areas such as Oncology, CNS, and Animal Health. Our in-house analytical capabilities are also well-suited to support new projects in these areas from early formulations to clinical trial material testing and release.” The financial terms of the transaction were not disclosed. About SpineThera SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its patented micro-suspension platform technology. SpineThera’s micro-suspension provides months long sustained release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SpineThera's flagship investigational drug product, SX600, is a groundbreaking dexamethasone acetate micro-suspension injection which has been meticulously engineered as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved benefit-risk pro to current epidural steroid injections for radicular leg pain. SpineThera, Inc., is based in Medical Alley, Minnesota, the global epicenter of health innovation and care. About ProMed Pharma ProMed Pharma specializes in the molding and extrusion of drug-loaded silicones, thermoplastics, and bioresorbable materials, leveraging this expertise to manufacture long-term implants and combination devices under cGMP. Working with both established and early-stage companies, we utilize robust manufacturing processes for controlled release of APIs utilizing a variety of materials. From clinical trial materials to commercial products, ProMed supports pharmaceutical and medical device companies developing controlled release formulations including subcutaneous, orthopedic, cardiovascular, and ophthalmic implants, intravaginal rings, and steroid-eluting combination components. The company has facilities in Plymouth and Maple Grove, Minnesota

Acquisition

05 Oct 2023

·www.biospace.com

SpineThera Celebrates Milestone Achievement with 6th Patent Issued by the US Patent and Trademark Office

PLYMOUTH, Minn.--(BUSINESS WIRE)-- SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced United States Patent and Trademark Office (USPTO) has issued Patent No. 11,771,707 related to its micro-suspension platform technology. Patent No. 11,771,707 provides additional protection for SX600 and complements previously issued U.S. Patent Nos. 8,927,529, 9,572,771, 10,350,222, 10,925,883, and 11,058,692. The newly granted ‘707’ patent underscores SpineThera’s ongoing dedication to developing novel medical technologies that enhance spinal health and improve patients' quality of life. The invention covered by this patent is a result of years of research and development by SpineThera’s team of skilled scientists, engineers, and medical professionals. “Our lead asset, SX600, is built on our micro-suspension platform technology, which is clinically proven to provide sustained-release of the active pharmaceutical ingredient for 90 days. This 6th US Patent provides additional depth and breadth to our patent portfolio covering our micro-suspension technology. We will continue to vigorously pursue development of SX600 with the aim of offering patients a non-opioid treatment for chronic sciatica pain,” said Jeff Missling, CEO of SpineThera. Recently SpineThera announced successful market research results for its lead asset SX600 showing a potential 70% adoption rate by physicians to treat patients suffering with lumbar radicular pain (sciatica). “This news, paired with strong clinical trial results in the phase-2 SALIENT trial, leads us to believe SX600 holds great potential to be a more effective sciatica pain management option for patients, and a leading drug in the non-opioid category,” Missling said. About SpineThera SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its patented micro-suspension platform technology. SpineThera’s micro-suspension provides months long sustained-release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SpineThera's flagship investigational drug product, SX600, is a groundbreaking dexamethasone acetate micro-suspension injection which has been meticulously engineered as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved benefit-risk pro to current epidural steroid injections for radicular leg pain. SpineThera is based in Medical Alley, Minnesota, the global epicenter of health innovation and care. View source version on businesswire.com: Contacts Jeff Missling, CEO jmissling@spinethera.com 612-508-4795 Source: SpineThera, Inc. View this news release online at:

25 Sep 2023

·www.biospace.com

SpineThera SALIENT Clinical Trial Results to Be Presented at Upcoming 22nd Annual ASRA Pain Medicine Meeting

PLYMOUTH, Minn.--(BUSINESS WIRE)-- SpineThera, Inc., a privately held, clinical-stage pharmaceutical company focused on the development of SX600 (a novel formulation of extended-release dexamethasone microspheres for transforaminal epidural injection [TF-EI] for the management of sciatica pain) today announced that the submitted abstract,” Clinically Meaningful Radicular Leg Pain Management via Novel Dexamethasone Extended Release Microsuspension (SX600)- PH1/2 Results” has been accepted for presentation at the 22nd Annual Pain Medicine Meeting hosted by the American Society of Regional Anesthesia and Pain Medicine (ASRA). This achievement is a significant milestone in the field of pain medicine. The well renowned conference is one of the premier events of the year, gathering experts, practitioners, and researchers from around the world to exchange knowledge, share innovative research, and discuss the latest advancements in pain management. This abstract was selected from a highly competitive pool of submissions highlighting groundbreaking research and advancements in pain medicine that have the potential to improve the lives of patients suffering from various pain conditions. SpineThera will be presenting their findings from the SALIENT Trial where clinically meaningful reduction in unilateral radicular leg pain with a favorable safety pro demonstrated for SX600 compared with placebo. The acceptance of this abstract underscores the dedication and expertise of the team at SpineThera. Chief Medical Officer, Dr. Lee Techner, will present the abstract at the conference. “We are excited to share these important clinical study results with the global pain medicine community and engage in meaningful discussions with fellow professionals at the ASRA conference” Dr. Techner said. The ASRA 22nd Annual Pain Medicine Meeting will take place November 10-11, 2023, in New Orleans. Attendees are encouraged to join the presentation to learn more about this groundbreaking research and the potential impact it may have on the field of pain medicine. About SpineThera SpineThera is a clinical stage pharmaceutical company working to improve the lives of patients by creating injectable drugs utilizing its patented micro-suspension platform technology. SpineThera’s micro-suspension provides months long sustained release of the active pharmaceutical ingredient with superior injectability at ultra-high concentrations. Our goal is to develop proprietary drugs that offer patients and physicians new treatment options that reduce risk, improve outcomes, and manage overall treatment costs in markets with few or no approved drugs. SpineThera's flagship investigational drug product, SX600, is a groundbreaking dexamethasone acetate micro-suspension injection which has been meticulously engineered as a targeted, extended-release corticosteroid with the potential to demonstrate a substantially improved benefit-risk pro to current epidural steroid injections for radicular leg pain. SpineThera, Inc., is based in Medical Alley, Minnesota, the global epicenter of health innovation and care. Spinethera.com View source version on businesswire.com: Contacts Jeff Missling, CEO jmissling@spinethera.com 612-508-4795 Source: SpineThera, Inc. View this news release online at:

100 Deals associated with Dexamethasone Acetate

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D02174	Dexamethasone Acetate	D07AB19 H02AB02 D10AA03 A01AC02 S02BA06 D07XB05 S03BA01 S01CB01 C05AA09 S01BA01 R01AD03	DB14649

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Multiple Myeloma	LI	Theravia Pharma SAS	16 Mar 2016
Multiple Myeloma	EU	Theravia Pharma SAS	16 Mar 2016
Multiple Myeloma	IS	Theravia Pharma SAS	16 Mar 2016
Multiple Myeloma	NO	Theravia Pharma SAS	16 Mar 2016
Endocrinology and Metabolic Disease	CN	Tianjin Jinyao Pharmaceutical Co., Ltd.	01 Jan 1981

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Intervertebral Disc Displacement	Phase 2	AU	SpineThera Australia PTY LTD	04 Nov 2019
Lumbar Radiculopathy	Phase 2	AU	SpineThera Australia PTY LTD	04 Nov 2019
Radicular Pain	Phase 2	AU	SpineThera Australia PTY LTD	04 Nov 2019
Radiculopathy	Discovery	AU	SpineThera Australia PTY LTD	04 Sep 2019

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03952377 (CTgov)	Phase 1/2	Radicular Pain \| Lumbar Radiculopathy \| Intervertebral Disc Displacement	56	Placebo (0.9% Sodium Chloride for Injection)	wbvkpavznn(ezulybaxne) = njhmkmsrgg hbocxucxky (sqdlrmotwa, iagotbhsnf - nidyqaxjdp) View more	-	10 Jan 2024
				SX600 (12.5 mg SX600)	wbvkpavznn(ezulybaxne) = dskqbietrh hbocxucxky (sqdlrmotwa, vqmgqijkfr - ippyatvgdh) View more
SALIENT (Biospace) Manual	Phase 2	Sciatica	56	SX600	(zgmxvvfyex) = irhhyvubuz pxjxixkqpj (cyknffoeog )	Positive	07 Dec 2022
				Placebo	(zgmxvvfyex) = vaeaedipxi pxjxixkqpj (cyknffoeog )
ASCO2005	Phase 2	Metastatic Solid Tumor	34	EPO+Dexa	vsojwfsdlk(zpmkcdfzws) = stgermabsn yvyuuokjbs (bstuyipsll ) View more	-	01 Jun 2005
NCT01756573 (CTgov)	Not Applicable	Pain	5	Bupivacaine (Bupivacaine)	kzajgfpqsj(wseaekncch) = blhbrhhayf neacqnddvn (fghbxuwvyl, cwzkwgwvqr - rriywjynqy) View more	-	14 May 2019
				Dexamthsone+Bupivacaine (Bupivacaine With Dexamethasone)	kzajgfpqsj(wseaekncch) = ojtgakhvwg neacqnddvn (fghbxuwvyl, yuefotrbbo - nzdtbgmbvi) View more
NCT02956070 (CTgov)	Not Applicable	Dentin Sensitivity \| Inflammation	70	Dexamethasone acetate (Experimental)	byjwnrskse(kxgpvbfzmf) = wcatldzpqs smgvvpbyid (uzgkfwkmyf, wmvydmnclw - hqmwvpjuir) View more	-	25 Nov 2020
				Potassium Nitrate (Placebo)	byjwnrskse(kxgpvbfzmf) = tweeubzjka smgvvpbyid (uzgkfwkmyf, dwgohmrqvq - yrxljqxbou) View more
NCT00651261 (CTgov)	Phase 3	FLT3 positive Acute Myeloid Leukemia	717	midostaurin+dexamethasone acetate+cytarabine+daunorubicin (Induction and Consolidation Chemotherapy Plus Midostaurin)	(jvlbzswvqu) = cqhhwihkjs cgiiarqbmg (ehkwbvhkjk, bgogyufotn - qykbzfsqym) View more	-	06 Feb 2017
				placebo+dexamethasone acetate+cytarabine+daunorubicin (Induction and Consolidation Chemotherapy Plus Placebo)	(jvlbzswvqu) = fatpxcqbxf cgiiarqbmg (ehkwbvhkjk, vhnwrhacgt - mqyvxnmmoh) View more